Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia

Venetoclax, an FDA-approved Bcl-2 selective inhibitor for the treatment of chronic lymphocytic leukemia and acute myeloid leukemia (AML), is tolerated well in elderly patients with AML and has good overall response rates; however, resistance remains a concern. In this study, we show that targeting C...

Descripción completa

Detalles Bibliográficos
Autores principales: Luedtke, Daniel A., Su, Yongwei, Ma, Jun, Li, Xinyu, Buck, Steven A., Edwards, Holly, Polin, Lisa, Kushner, Juiwanna, Dzinic, Sijana H., White, Kathryn, Lin, Hai, Taub, Jeffrey W., Ge, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042303/
https://www.ncbi.nlm.nih.gov/pubmed/32296028
http://dx.doi.org/10.1038/s41392-020-0112-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042303/
https://www.ncbi.nlm.nih.gov/pubmed/32296028
http://dx.doi.org/10.1038/s41392-020-0112-3

Ejemplares similares